Decera Clinical Education Oncology Podcast

In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:Optimal use of approved CAR T-cell therapies for lymphoma and ALLInvestigational CAR T-cell therapies for multiple myelomaManaging CAR T-cell therapy–related toxicitiesPresenters:Michael R. Bishop, MDProfessor of MedicineSection of Hematology/OncologyDirector, Cellular Therapy ProgramUniversity of ChicagoChicago, IllinoisDaniel J. DeAngelo, MD, PhDProfessor of MedicineDepartment of MedicineHarvard Medical SchoolChief, Division of LeukemiaDepartment of Medical OncologyDivision of Hematologic MalignanciesDana‐Farber Cancer InstituteBoston, MassachusettsNoopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.Link to full program:https://bit.ly/3iyt5zQ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:• Treatment sequencing with IO and TKI therapies• Optimizing dose for patients with preexisting toxicities• Considerations for local control of metastatic sites • Ongoing clinical trials Presenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.Link to full program:https://bit.ly/32IS9gx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:• Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial • Selecting therapy for a patient with lenalidomide-refractory disease at first relapse• How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms• Key findings from the DREAMM2 trial on belantamab mafodotin• Monitoring and management strategies for ocular toxicity with belantamab mafodotinPresenters:Jesús F. San-Miguel, MD, PhDDirector of Clinical and Translational MedicineUniversidad de NavarraPamplona, SpainPaula Rodriguez-Otero, MD, PhDAssociate ProfessorConsultant in HematologyDepartment of Hematology, Clínica Universidad de NavarraUniversity of NavarraPamplona, SpainProf. Dr. med. Katja Weisel Deputy DirectorII. Medical Clinic and PolyclinicDepartment of Oncology and HematologyDepartment of Pneumology and Bone Marrow TransplantationUniversity Medical Center Hamburg-EppendorfHamburg, GermanyContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program, including associated downloadable slidesets: https://bit.ly/2QRqYuC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more.Presenters:Natalie S. Callander, MDProfessor of Medicine Director, Myeloma Clinical Program University of Wisconsin Carbone Cancer CenterMadison, WisconsinShaji Kumar, MDDepartment of HematologyMayo ClinicRochester, MinnesotaContent based on an online CME program supported by educational grants from GlaxoSmithKline LLC and Sanofi Genzyme.Link to full program, including associated downloadable slidesets: https://bit.ly/3gT324y Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcinoma (RCC). Topics include:Choice of first-line therapyCombinations of targeted agents and immunotherapyCombinations of immune checkpoint inhibitorsActive surveillance and monitoringCytoreductive nephrectomyPresenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, Pfizer and EMD Serono, and Merck Sharp & Dohme Corp.Link to full program: https://bit.ly/32IS9gx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:ASPEN: Zanubrutinib vs ibrutinib in WMOASIS: Ibrutinib, venetoclax, and obinutuzumab in MCLGHSG HD17: PET-guided therapy in HLKEYNOTE-024: Pembrolizumab vs brentuximab in HLALEXANDER: AUTO3 in DLBCLPresenters:Jennifer R. Brown, MD, PhDAssociate Professor of MedicineDepartment of Hematologic MalignanciesDana-Farber Cancer InstituteHarvard Medical SchoolDirector, CLL CenterDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsJohn Allan, MDAssistant Professor of MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program: https://bit.ly/3aSfekM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET exon 14 testing and selecting MET-targeted therapies for patients with advanced NSCLC with topics including:Incorporating MET exon 14 testing into standard of careComparison of RNA-based and DNA-based NGS platformsAvailability of RNA-based NGS testing around the worldUsing FISH to quantify MET copy gain/amplificationRegulatory and clinical differences between new, selective MET inhibitorsSafety profiles of type I vs type II MET inhibitorsCounseling patients on management of peripheral edema, a class effect with MET inhibitor therapyInsights on combining MET inhibition with immune checkpoint inhibition therapy or chemotherapySelecting second-line therapy for a patient with MET exon 14–altered NSCLC progressing on tepotinib or capmatinibPresenters:Luis Paz-Ares, MD, PhDMedical OncologyUniversity Hospital Doce de OctubreMadrid, SpainD. Ross Camidge, MD, PhDProfessor of Medicine/OncologyUniversity of Colorado Cancer CenterAurora, ColoradoKaren L. Reckamp, MD, MSProfessor of MedicineDirector, Division of Medical OncologyDepartment of MedicineCedars SinaiLos Angeles, CaliforniaContent based on an online CME program supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.Link to full program, including associated downloadable slidesets:https://bit.ly/2ExadCf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCLC with topics including:Whether testing for MET exon 14 status should be standard of careParallel vs sequential testing by DNA-based vs RNA-based NGSCo-occurring driver mutations in patients with METex14 mutation–positive NSCLCOptimal use of immune checkpoint inhibitor–based therapy in the setting of METex14-positive disease, including sequencing with MET inhibitor–based therapyEMA regulatory considerations for the new, selective MET inhibitors tepotinib and capmatinibPresenters:Luis Paz-Ares, MD, PhD Medical OncologyUniversity Hospital Doce de OctubreMadrid, SpainD. Ross Camidge, MD, PhDProfessor of Medicine/OncologyUniversity of Colorado Cancer CenterAurora, ColoradoKaren L. Reckamp, MD, MSProfessor of MedicineDirector, Division of Medical OncologyDepartment of MedicineCedars SinaiLos Angeles, CaliforniaLink to full program, including associated downloadable slidesets: https://bit.ly/2ExadCf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Anna F. Farago, MD, PhD, and Taofeek K. Owonikoko, MD, PhD, answer questions focused on the topic of current and evolving use of immunotherapy in patients with advanced small-cell lung cancer with topics including:Selecting between atezolizumab and durvalumab in the frontline settingIntegration of lurbinectedin, a novel anticancer drug that was recently approved for the treatment of relapsed SCLC after platinum-based chemotherapy, into patient careWhich patients should receive salvage therapy with an immune checkpoint inhibitor in the third-line settingManagement of brain metastases in patients with advanced SCLCPresenters:Anna F. Farago, MD, PhDAssistant Professor of MedicineDepartment of MedicineHarvard Medical SchoolAssistant in MedicineDivision of Hematology/OncologyDepartment of MedicineMassachusetts General HospitalBoston, Massachusetts Taofeek K. Owonikoko, MD, PhDProfessorDepartment of Hematology and Medical OncologyCo-Leader, Thoracic OncologyEmory UniversityAtlanta, GeorgiaContent based on an online CME program supported by educational grants from Genentech, a member of the Roche Group, and Merck Sharp & Dohme Corp. Link to full program, including associated downloadable slidesets: https://bit.ly/3aTzthZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:ASCEND: acalabrutinib vs idelalisib plus rituximab or BRACE-CL-001: acalabrutinib long-term efficacyCLL14: Venetoclax plus obinutuzumabCLARITY: Ibrutinib plus venetoclaxMeasurable residual disease (MRD)Complex karyotypesZanubrutinib plus obinutuzumab and venetoclaxPresenters:Jennifer R. Brown, MD, PhDAssociate Professor of MedicineDepartment of Hematologic MalignanciesDana-Farber Cancer InstituteHarvard Medical SchoolDirector, CLL CenterDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsJohn Allan, MDAssistant Professor of MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program: https://bit.ly/3aSfekM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:FLT3 inhibitors crenolanib and quizartinibAnti-CD47 antibody magrolimabIMGN632, a CD123 antibody–drug conjugateAnti-CD70 antibody cusatuzumabAPR-246, targeting the TP53 mutationContent is part of an online CME program supported by an educational grant from Daiichi-Sankyo.Link to full program, including a ClinicalThought commentary: https://bit.ly/2Y2uCG2 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including:Best practices in testing for NTRK fusions in solid tumorsOptimal use of approved TRK inhibitorsKey adverse events with TRK inhibitors and management strategiesEmerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agentsPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental Therapeutics Director, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, Thoracic OncologyMemorial Sloan Kettering Cancer CenterNew York, New YorkPashtoon Kasi, MDAssistant ProfessorCollege of Medicine and OncologyHolden Comprehensive Cancer CenterUniversity of IowaIowa City, IowaContent based on an online CME program supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Genentech.Link to full program: https://bit.ly/2PN0BWh Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including:Frontline Management of Chronic-Phase CMLSelection of TKI Based on Goal of Treatment-Free RemissionChanging TKIs due to Intolerance: Second-line Therapy and Toxicity ManagementChanging TKIs due to CML Progression: Second-line Therapy and Future OptionsPresenters:Prof. Dr. med Tim Henrik BrümmendorfHeadDepartment of Hematology, Oncology, Hematostaseology, and Stem Cell TransplantationUniversity Hospital Aachen, RWTH AachenAachen, GermanyJorge Cortes, MDDirector, Georgia Cancer CenterEminent Scholar, Georgia Research AcademyAugusta, Georgia, USACarlo Gambacorti-Passerini, MDProfessor, HematologyUniversity Milano BicoccaDirector, HematologySan Gerardo HospitalMonza, Italy Content based on an online CME program supported by an educational grant from Pfizer Inc.Link to full program, including associated downloadable slidesets: https://bit.ly/30P8Uaf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including:How to approach discordant results with liquid vs tissue biopsiesRepeating NGS testing at progressionSelecting urgent treatment when molecular results are not yet availablePoint mutations in NTRK fusion–positive diseaseSelecting second-line therapy for EGFR-positive disease with high PD-L1 expression after first-line TKISelecting first-line and second-line therapy for ROS1-positive diseaseStandard of care for MET-altered diseaseSelecting second-line therapy for RET fusion–positive disease after first-line TKIPresenters:Edward S. Kim, MD, FACPChair, Solid Tumor Oncology and Investigational TherapeuticsDonald S. Kim Distinguished Chair for Cancer ResearchLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaLeora Horn, MD, MSc, FRCPCIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt Ingram Cancer CenterNashville, TennesseeContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as:Selecting immuno-oncology vs targeted therapy in MSI-high cancers with co-occurring alterations (eg, BRCA, HER2, BRAF, NTRK)Switching to a new immuno-oncology strategy at progression on first-line immune checkpoint inhibitionNeoadjuvant treatment with immune checkpoint inhibitorsFinancial considerations when selecting chemotherapy vs immuno-oncologyPresenters:John L. Marshall, MDChief, Division of Hematology/OncologyDepartment of MedicineGeorgetown University HospitalWashington, DCJamie E. Chaft, MDAssociate Attending PhysicianThoracic Oncology ServiceMemorial Sloan Kettering Cancer CenterNew York, New YorkScot Niglio, MDMedical OncologistBethesda, MarylandContent based on an online CME program supported by an educational grant from Merck Sharp & Dohme Corp.Link to full program:https://bit.ly/31vQtqb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced non-small-cell lung cancer with topics including:Selecting therapy for advanced NSCLC without actionable mutations and with different levels of PD-L1 expressionChoosing therapy for advanced NSCLC with an actionable mutation on NGS and high PD-L1 expressionLeveraging key data from CheckMate 9LA to identify patients who may benefit from chemotherapy plus nivolumab/ipilimumabSTK11/KEAP1 as potential predictors for a lack of response to immune checkpoint inhibitor–based therapyTreatment for NSCLC after progression on chemotherapy plus an immune checkpoint inhibitorRechallenging after stopping immune checkpoint inhibitor due to immune-related adverse eventsPresenters:Edward S. Kim, MD, FACPChair, Solid Tumor Oncology and Investigational TherapeuticsDonald S. Kim Distinguished Chair for Cancer ResearchLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaLeora Horn, MD, MSc, FRCPCIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt Ingram Cancer CenterNashville, TennesseeContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.